GENOMIC VISION overview

Regulatory News: Genomic Vision (FR0011799907 – GV, – the “Company”) , a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the launch of its new service, HexaCard. HexaCard is an application of Genomic Vision's proprietary Molecular Combing Technology (MCT) that offers precise visualization and measurement of individual DNA molecules. HexaCard aims to consolidate multiple...

Regulatory News: Genomic Vision (FR0011799907 – GV, – the “Company”) (Paris:GV), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announces the issuance of the third tranche of convertible notes with equity warrants attached (OCABSA) for a total net amount of €1.92 million. In a press release dated May 20, 2022, the Company announced the signing of a contract with Winance on April 11, 2022 as...

Regulatory News: Genomic Vision (FR0011799907 – GV, – the “Company”) , a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce an exclusive European distribution agreement with CliniSciences. CliniSciences is a major European distributor of innovative products and services in Life Science Research with a particular focus on oncology. CliniSciences and Genomic Vision will work closely...

Regulatory News: Genomic Vision (FR0011799907 – GV, – the “Company”) , a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announces an agreement with The Institute of Cancer Research, London, for the purchase of the Company’s FiberVision ® S and FiberSmart ® products. The agreement includes an upfront, one-off payment in addition to annual recurring revenues from sales of consumable products...

Regulatory News: Genomic Vision (FR0011799907 – GV, – the “Company”) , a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to provide a business update on its refocused strategy. Under new leadership, Genomic Vision is committed to delivering high-quality genomic solutions that play a critical role in improving quality control and bioproduction standards, supporting the development of advanced...

Regulatory News: Genomic Vision (FR0011799907 – GV, – the “Company”) , a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, today announced its revenue and cash position for the first quarter ended on March 31, 2023 1 . Q1 2023 revenue In € thousands –IFRS standards Q1 2023 Q1 2022 ∆% Total revenue from sales 321 284 +13% Other revenue 113 104 +9% Total revenue from activity 435 389 +12% Total revenue...